



S.F. No. 2806 – Changing provisions in the prescription monitoring program (as proposed to be amended by the A-1 amendment)

Author: Senator Zaynab Mohamed

Prepared by: Erica Heikel, Senate Counsel (erica.heikel@mnsenate.gov)

Date: March 26, 2025

Bill Overview

S.F. No. 2806 modifies Minnesota’s Prescription Monitoring Program (PMP) by replacing the term “controlled substances” with “reportable substances” in reference to those substances that must be submitted to the PMP. Current law provides that pharmacies and prescribers who dispense Schedule II, III, IV, and V substances, butalbital, and gabapentin, must submit prescription data to the PMP. The modification of terms is made in Section 1 through 7 of the bill. Notably, S.F. No. 2806 also adds opioid antagonists to the list of substances that must be reported to the PMP.

Section Summaries

Section 1 (amends Minn. Stat. § 152.126, subd. 1; Definitions) amends the definition of “controlled substances” by replacing it with “reportable substances.” The use of the term “reportable substances” is limited to the purposes of section 152.126. This section also adds opioid antagonists approved for use by the FDA as opioid overdose reversal agents to the definition of substances that must be reported to the PMP.

Sections 2 – 4; Section 7 replace the term “controlled substances” with “reportable substances.” Replacing the terms are the only changes made in these sections.

Section 5 (amends Minn. Stat. § 152.126, subd. 5; Use of data by board) adds permission to the Board of Pharmacy to maintain deidentified data reported to the PMP for the specific purposes of collecting, reviewing, and analyzing prescription information, or for review by those authorized personnel working on designing, evaluating, implementing, or maintaining the PMP.

Section 6 (amends Minn. Stat. § 152.126, subd. 5; Access to reporting system data) adds a paragraph providing that access to reportable data on opioid antagonists is restricted to board personnel who are collecting, reviewing, and analyzing prescription information and to authorized personnel working on designing, evaluating, implementing, or maintaining the PMP.



Senate Counsel, Research, and Fiscal Analysis provides nonpartisan legislative, legal, fiscal, and analytical services to the Minnesota Senate. This document can be made available in different formats upon request.

www.senate.mn/scrfa/home | 651-296-4791
95 University Ave. W, STE 3300, Saint Paul, MN, 55155